用于常规临床实践中准确诊断外周T细胞淋巴瘤亚型的基因表达特征
研究基于105例训练队列的基因表达谱数据,在FFPE组织中建立并验证了外周T细胞淋巴瘤(PTCL)分子分型分类器,并在140例验证队列中与三位专家血液病理学家的病理诊断进行比较。该分类器在85%(119例)的病例中与病理诊断一致,在8%(11例)的病例中不一致,并可能改善部分病例的诊断。
要点
- 在FFPE组织中建立的转录组分类器对PTCL亚型分类的灵敏度>80%、特异度>95%、准确率>94%。
- 验证队列中分类器与专家病理诊断一致率为85%(119例),不一致率为8%(11例)。
- 分子分型可提供包括病毒病因和易位伙伴在内的PTCL亚型综合分子特征。
核心结论
- 研究开发了一种新的转录组学方法用于PTCL亚型分类,相比传统病理诊断具有更高的精确性和一致性,有助于转化为临床实践。
研究设计与样本
- 训练队列纳入105例特征明确的PTCL病例,使用新鲜冷冻组织和HG-U133plus2.0平台(Affymetrix公司)进行基因表达谱分析以推导诊断特征,随后在匹配的FFPE组织中用数字基因表达谱平台(nCounter,NanoString Technologies公司)验证。
- 另在一个140例PTCL队列中经严格病理复核和辅助检测验证该转录组分类器。
主要发现
- 在训练队列的FFPE组织中, refined转录组分类器与新鲜冷冻衍生的诊断模型相比,对PTCL亚型分类的灵敏度>80%、特异度>95%、准确率>94%,并在三个独立实验室间显示高可重复性。
- 在验证队列中,转录组分类器与三位专家血液病理学家作出的病理诊断在85%(119例)的病例中一致,在6%(8例)的病例中与分子特征呈临界关联,在8%(11例)的病例中不一致。
- 分类器在2例中改善了病理诊断,并经临床发现验证;在11例不一致病例中,有4例的分子分型基于整体转录组和形态学特征可能优于病理诊断。
- 分子分型提供了PTCL亚型的全面分子特征,包括病毒病因因素和易位伙伴。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression-based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND METHODS: We assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays. RESULTS: In the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen-derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners. CONCLUSION: We developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.
引用
- Amador C, Bouska A, Wright G, et al. Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. J Clin Oncol. 2022. PMID: 35839444. doi:10.1200/JCO.21.02707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。